MesotheliomaUSA.net Mesothelioma WHAT IS THE SURVIVAL RATE FOR PATIENTS WITH METASTATIC MESOTHELIOMA

WHAT IS THE SURVIVAL RATE FOR PATIENTS WITH METASTATIC MESOTHELIOMA

Spread the love

Malignant mesothelioma is a rare and aggressive cancer that develops in the mesothelial cells that line the body’s internal organs. It is usually caused by exposure to asbestos fibers, which can become lodged in the lungs and other organs and cause chronic inflammation that leads to cancer. Mesothelioma is generally classified as “localized” if it is confined to the site of origin, or “metastatic” if it has spread to other parts of the body.

Metastatic mesothelioma is a particularly challenging form of the disease, as it has usually spread to distant sites before it is diagnosed, making treatment more difficult. The survival rate for patients with metastatic mesothelioma is generally lower than for those with localized disease, as the cancer is more advanced and less responsive to treatment.

Read also:  WHAT ARE THE CHANCES OF SURVIVAL FOR STAGE 2B MESOTHELIOMA

Unfortunately, the prognosis for patients with metastatic mesothelioma is generally poor, with a median survival time of around 12 months. However, survival rates can vary depending on a number of factors, including the location and extent of the metastases, the patient’s age and overall health, and the type and stage of the mesothelioma.

One study published in the Journal of Thoracic Oncology in 2020 looked at the survival outcomes for 385 patients with metastatic pleural mesothelioma (the most common form of the disease, affecting the lining of the lungs). The study found that the median overall survival time was just over 10 months, and that several factors were associated with better outcomes.

These factors included younger age (under 65), female gender, epithelioid histology (a subtype of mesothelioma that is generally associated with a better prognosis), and treatment with systemic therapy (chemotherapy or immunotherapy). However, even among patients who received systemic therapy, the median survival time was only around 14 months.

Read also:  HOW CAN I FIND A SPECIALIST WITH EXPERIENCE IN DIAGNOSING AND TREATING PERITONEAL MESOTHELIOMA

Another study, published in the European Respiratory Journal in 2019, looked at the survival outcomes for 441 patients with metastatic mesothelioma of all types. The study found that the median overall survival time was just over 9 months, and that several factors were associated with better outcomes.

These included younger age (under 60), female gender, non-epithelioid histology (a subtype of mesothelioma that is generally associated with a worse prognosis), and treatment with systemic therapy. However, even among patients who received systemic therapy, the median survival time was only around 12 months.

Other factors that may affect survival outcomes for patients with metastatic mesothelioma include the location and extent of the metastases. For example, metastases to the brain or liver may be more difficult to treat and may lead to a poorer prognosis.

Read also:  WHAT IS THE SUCCESS RATE OF MULTIMODAL THERAPY FOR MESOTHELIOMA

In summary, the survival rate for patients with metastatic mesothelioma is generally poor, with a median survival time of around 10-12 months. However, survival rates can vary depending on a number of factors, including the patient’s age, gender, overall health, and the type and stage of the mesothelioma. Treatment with systemic therapy may also improve outcomes, but even among patients who receive such treatment, survival times are generally limited.


Spread the love

Leave a Reply

Your email address will not be published. Required fields are marked *